Abstract Number: 712 • 2016 ACR/ARHP Annual Meeting
Efficacy of Golimumab for Nonradiographic Axial Spondyloarthritis (nr-axSpA): Subgroup Analysis By Baseline MRI and C-Reactive Protein Status
Background/Purpose: Efficacy of golimumab (GLM) for nr-axSpA was demonstrated in a randomized, double-blind (DB), placebo (PBO)-controlled, phase 3 study (GO-AHEAD; NCT01453725).1 In a subgroup analysis,…Abstract Number: 2148 • 2016 ACR/ARHP Annual Meeting
Recruitment of Circulating Monocytes By TNF/IL-6-Induced Expression of Vascular Cell Adhesion Molecule 1 (VCAM-1) Drives Valvular Inflammation in K/B/g7 Mice
Background/Purpose: Cardiovascular (CV) comorbidity is common in rheumatic diseases and includes accelerated atherosclerosis and inflammatory valvular heart disease (iVHD). KRN T cell receptor (TCR) transgenic…Abstract Number: 2987 • 2016 ACR/ARHP Annual Meeting
Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
Background/Purpose: Head-to-head comparisons of biological (b)DMARDs in the treatment of RA should provide rigorous evidence on the comparative efficacy of different treatments. Although there are…Abstract Number: 532 • 2016 ACR/ARHP Annual Meeting
The DAS28 Score May Misread Disease Activity in Rheumatoid Arthritis Patients
Background/Purpose: The DAS28 is a measure of disease activity in rheumatoid arthritis (RA). DAS28 stands for 'disease activity score' and the number 28 refers to…Abstract Number: 728 • 2016 ACR/ARHP Annual Meeting
Correlation Between the Spinal MRI Findings and the Serum Level of DKK-1 in Patients with Spondyloarthritis Treated with TNF Antagonist
Background/Purpose : Recent prospective data suggest that spinal inflammatory damage in patients with ankylosing spondylitis will eventually convert into fat. In these complex inflammatory lesions,…Abstract Number: 2232 • 2016 ACR/ARHP Annual Meeting
Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
Title: Above-Label Dosing with Biologics in Treatment-Naïve and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2…Abstract Number: 3014 • 2016 ACR/ARHP Annual Meeting
Tapering of Adalimumab Based on Therapeutic Drug Monitoring in Rheumatoid Arthritis
Background/Purpose: Treatment with biologicals is based on the principle of ‘one size fits all’ without taking differences into account for dosing schemes, patients’ characteristics and…Abstract Number: 595 • 2016 ACR/ARHP Annual Meeting
Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability, loss of productivity and reduced quality of life. In established and early RA, compared with MTX…Abstract Number: 916 • 2016 ACR/ARHP Annual Meeting
Novel Immunosignature Stratifies Patients with Rheumatoid Arthritis into Distinct Disease Sub-Groups and Predicts Response to Anti-Tnfα Therapies
Background/Purpose: Autoimmune rheumatic diseases, including rheumatoid arthritis (RA), have multifactorial pathogenesis associated with failure of immune tolerance. Advances in understanding the disease immunopathology have led…Abstract Number: 2234 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis
Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2 Affiliations: 1Hospital for Special Surgery, New York, NY, US; 2Novartis Pharmaceuticals Corporation, East Hanover,…Abstract Number: 3065 • 2016 ACR/ARHP Annual Meeting
Mortality in Patients with Rheumatoid Arthritis and Interstitial Lung Disease Treated with First Line TNFi or Rituximab Therapies
Mortality in Patients With Rheumatoid Arthritis and Interstitial Lung Disease Treated With First Line TNFi or Rituximab Therapies Druce KL, Iqbal K, Watson K, Symmons…Abstract Number: 597 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015
Background/Purpose: Although evidence from randomized trials suggest similar efficacy and safety on a group level for the different anti-TNF drugs available for the treatment of…Abstract Number: 947 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results
Background/Purpose: Juvenile idiopathic arthritis (JIA) often requires biologic medication to control polyarticular disease courses. This study assesses the pharmacokinetics (PK), efficacy and safety of certolizumab…Abstract Number: 2250 • 2016 ACR/ARHP Annual Meeting
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Background/Purpose: Advanced therapies including bDMARDs and tofacitinib have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim…Abstract Number: 3067 • 2016 ACR/ARHP Annual Meeting
Treatment Decisions Following Diagnosis of Cancer during TNFi Inhibitor Treatment in Patients with Rheumatoid Arthritis: Results from the BSRBR-RA
Treatment Decisions Following Diagnosis of Cancer During TNFi inhibitor Treatment in Patients with Rheumatoid Arthritis: results from the BSRBR-RA Druce KL, De Cock D, Watson…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 29
- Next Page »